- Home
- CHEK vs KTTA Comparison
CHEK vs KTTA Comparison
Compare CHEK & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- KTTA
- Stock Information
- Founded
- CHEK 2004
- KTTA 2020
- Country
- CHEK Israel
- KTTA United States
- Employees
- CHEK N/A
- KTTA N/A
- Industry
- CHEK Medical Electronics
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- CHEK Health Care
- KTTA Health Care
- Exchange
- CHEK Nasdaq
- KTTA Nasdaq
- Market Cap
- CHEK 4.5M
- KTTA 5.1M
- IPO Year
- CHEK 2015
- KTTA 2021
- Fundamental
- Price
- CHEK $0.67
- KTTA $0.71
- Analyst Decision
- CHEK
- KTTA
- Analyst Count
- CHEK 0
- KTTA 0
- Target Price
- CHEK N/A
- KTTA N/A
- AVG Volume (30 Days)
- CHEK 26.5K
- KTTA 91.3K
- Earning Date
- CHEK 08-26-2025
- KTTA 08-14-2025
- Dividend Yield
- CHEK N/A
- KTTA N/A
- EPS Growth
- CHEK N/A
- KTTA N/A
- EPS
- CHEK N/A
- KTTA N/A
- Revenue
- CHEK N/A
- KTTA N/A
- Revenue This Year
- CHEK N/A
- KTTA N/A
- Revenue Next Year
- CHEK N/A
- KTTA N/A
- P/E Ratio
- CHEK N/A
- KTTA N/A
- Revenue Growth
- CHEK N/A
- KTTA N/A
- 52 Week Low
- CHEK $0.56
- KTTA $0.65
- 52 Week High
- CHEK $3.04
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- CHEK 40.79
- KTTA 45.63
- Support Level
- CHEK $0.59
- KTTA $0.66
- Resistance Level
- CHEK $0.68
- KTTA $0.72
- Average True Range (ATR)
- CHEK 0.04
- KTTA 0.04
- MACD
- CHEK 0.00
- KTTA 0.00
- Stochastic Oscillator
- CHEK 46.45
- KTTA 39.04
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).